NASDAQ:RNAZ

TransCode Therapeutics (RNAZ) Stock Forecast, Price & News

$3.21

-0.79 (-19.75%)

(As of 06/6/2023 ET)

Compare

Today's Range: $3.12
▼
$3.81
50-Day Range: $3.94
▼
$123.80
52-Week Range: $3.12
▼
$42.00

Volume: 4.22 million shs
Average Volume: 101,363 shs
Market Capitalization: $2.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $200.00

TransCode Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,638.3% Upside
$120.00 Price Target
Short Interest: Healthy
2.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($17.40) to ($15.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
TransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $120.00, TransCode Therapeutics has a forecasted upside of 3,638.3% from its current price of $3.21.
Amount of Analyst Coverage
TransCode Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.81% of the outstanding shares of TransCode Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
TransCode Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TransCode Therapeutics has recently decreased by 96.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TransCode Therapeutics does not currently pay a dividend.
Dividend Growth
TransCode Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNAZ.

0.6

News and Social Media Coverage

Search Interest
Only 3 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
2 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.50% of the stock of TransCode Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.92% of the stock of TransCode Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($17.40) to ($15.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TransCode Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TransCode Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TransCode Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TransCode Therapeutics (NASDAQ:RNAZ) Stock

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Receive RNAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAZ Stock News Headlines

June 6, 2023 | finance.yahoo.com

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma

May 22, 2023 | markets.businessinsider.com

TransCode Announces 1-for-20 Reverse Stock Split

June 6, 2023 | Vantage Point (Ad)

Stop Trading Like A Turtle

Performing at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah?

May 22, 2023 | finance.yahoo.com

TransCode Therapeutics Announces 1-for-20 Reverse Stock Split

May 19, 2023 | americanbankingnews.com

TransCode Therapeutics (NASDAQ:RNAZ) and Terns Pharmaceuticals (NASDAQ:TERN) Head-To-Head Contrast

May 11, 2023 | marketwatch.com

8-K: Transcode Therapeutics, Inc.

April 27, 2023 | finance.yahoo.com

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial

April 26, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio

June 6, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

April 14, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas

April 14, 2023 | americanbankingnews.com

Ventyx Biosciences (NASDAQ:VTYX) and TransCode Therapeutics (NASDAQ:RNAZ) Head to Head Analysis

April 6, 2023 | msn.com

Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

April 6, 2023 | finance.yahoo.com

TransCode Therapeutics to present at AACR Annual Meeting 2023

April 5, 2023 | finanznachrichten.de

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock

April 5, 2023 | finance.yahoo.com

TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138

April 5, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock

April 3, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock

April 2, 2023 | finanznachrichten.de

TransCode Therapeutics, Inc.: TransCode Therapeutics Reports 2022 Results; Provides Business Update

March 31, 2023 | finance.yahoo.com

TransCode Therapeutics Reports 2022 Results; Provides Business Update

February 28, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer

February 22, 2023 | uk.finance.yahoo.com

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

February 18, 2023 | finance.yahoo.com

Great news for TransCode Therapeutics, Inc. (NASDAQ:RNAZ): Insiders acquired stock in large numbers last year

February 17, 2023 | finance.yahoo.com

TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

February 16, 2023 | finance.yahoo.com

TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

February 1, 2023 | finance.yahoo.com

Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

February 1, 2023 | msn.com

Why Is TransCode Therapeutics (RNAZ) Stock Up 45% Today?

January 31, 2023 | finance.yahoo.com

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

See More Headlines

RNAZ Price History

30 days | 90 days | 365 days | Advanced Chart

RNAZ Company Calendar

Last Earnings: 3/31/2023
Today: 6/06/2023
Next Earnings (Estimated): 6/12/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RNAZ
CUSIP: N/A
CIK: 1829635
Web: www.transcodetherapeutics.com
Phone: 857-837-3099
Fax: N/A
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $120.00
High Stock Price Forecast: $120.00
Low Stock Price Forecast: $120.00
Forecasted Upside/Downside: +6,209.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($27.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -319.51%
Return on Assets: -192.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.80
Quick Ratio: 0.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.99 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 790,000
Free Float: 676,000
Market Cap: $2.50 million
Optionable: Not Optionable
Beta: -0.33

Key Executives

Mr. Robert Michael Dudley (Age 72)
Co-Founder, CEO, Pres & Director
Comp: $495.48k

Mr. Thomas A. Fitzgerald M.B.A. (Age 71)
CFO, VP of Admin. & Director
Comp: $317.61k

Dr. Zdravka Medarova Ph.D. (Age 48)
Co-Founder & CTO

Dr. Anna Moore Ph.D. (Age 61)
Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Dr. Qiyong Peter Liu Ph.D. (Age 59)
VP of R&D and Chief Scientist

Mr. Alan Freidman
VP of Investor Relations

Key Competitors

View All Competitors

Insiders

Robert Michael Dudley
Bought 1,000 shares on 9/14/2022
Total: $23,000.00 ($23.00/share)

View All Insider Transactions

RNAZ Stock - Frequently Asked Questions

Should I buy or sell TransCode Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNAZ shares.
View RNAZ analyst ratings or view top-rated stocks.
What is TransCode Therapeutics' stock price forecast for 2023?: 1 equities research analysts have issued 12 month target prices for TransCode Therapeutics' stock. Their RNAZ share price forecasts range from $120.00 to $120.00. On average, they predict the company's stock price to reach $120.00 in the next twelve months. This suggests a possible upside of 3,685.5% from the stock's current price.
View analysts price targets for RNAZ or view top-rated stocks among Wall Street analysts.
How have RNAZ shares performed in 2023?: TransCode Therapeutics' stock was trading at $13.46 at the beginning of 2023. Since then, RNAZ stock has decreased by 76.4% and is now trading at $3.17.
View the best growth stocks for 2023 here.
Are investors shorting TransCode Therapeutics?: TransCode Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 22,200 shares, a decline of 96.6% from the April 30th total of 653,200 shares. Based on an average daily trading volume, of 44,200 shares, the days-to-cover ratio is presently 0.5 days.
View TransCode Therapeutics' Short Interest.
When is TransCode Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 12th 2023.
View our RNAZ earnings forecast.
How were TransCode Therapeutics' earnings last quarter?: TransCode Therapeutics, Inc. (NASDAQ:RNAZ) issued its quarterly earnings data on Friday, March, 31st. The company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($7.60) by $0.20.

When did TransCode Therapeutics' stock split?: TransCode Therapeutics's stock reverse split before market open on Tuesday, May 23rd 2023. The 1-20 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
When did TransCode Therapeutics IPO?: (RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at $4.00 per share.
What is TransCode Therapeutics' stock symbol?: TransCode Therapeutics trades on the NASDAQ under the ticker symbol "RNAZ."
How do I buy shares of TransCode Therapeutics?: Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TransCode Therapeutics' stock price today?: One share of RNAZ stock can currently be purchased for approximately $3.17.
How much money does TransCode Therapeutics make?: TransCode Therapeutics (NASDAQ:RNAZ) has a market capitalization of $2.50 million. The company earns $-17,570,000.00 in net income (profit) each year or ($27.00) on an earnings per share basis.
How can I contact TransCode Therapeutics?: TransCode Therapeutics' mailing address is 6 LIBERTY SQUARE 2382, BOSTON MA, 02109. The official website for the company is www.transcodetherapeutics.com. The company can be reached via phone at 857-837-3099 or via email at alan.freidman@transcodetherapeutics.com.

This page (NASDAQ:RNAZ) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial